An interventional study of Testing for mutation status in Non Small Cell Lung Cancer, sponsored by AstraZeneca. Completed at 36 sites in 7 countries. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2011-08-08.
Sponsored by AstraZeneca · Not applicable, Interventional, and Screening
The purpose of this study is to study the changes in protein in lung cells of Asian patients with advanced non small cell lung cancer.
A molecular epidemiology study in Asian patients with advanced NSCLC of adeno histology to assess EGFR mutation status.
7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.
This study's planned enrollment of 1,270 is above the median of 60 across 5,295 interventional studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
EGFR mutation testing
Procedure: Testing for mutation status
EGFR mutation test
EGFR mutation status of Asian patients with advanced NSCLC
Time frame: Samples will be tested after informed consent. Mutation results will be available within 1-3 weeks.
This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca